Subscribe via RSS- NEWS ARCHIVES
-
2008
2007
2006
2005
2004
Pharma & Bio Ingredients
Shares of Biomira rose 21 cents, or 17 percent, to $1.45 in morning trading on the Nasdaq. Shares have traded between $1.20 and $2.24 over the past 52 weeks.
An analysis of data from a mid-stage clinical trial showed that cancer patients given the company's Stimuvax plus supportive care lived an average of 30.6 months following treatment, compared with the average 13.3 months in patients who received supportive care alone.
The study followed 171 patients with advanced lung cancer who had just had their disease stabilized with first-line chemotherapy with or without radiation therapy. Previously, the company had referred to Stimuvax as BLP25 Liposome Vaccine. Supportive care was defined as second-line chemotherapy with or without radiation.
The company said it has started transferring the project to its partner, the German drug maker Merck KGaA, and has started to make batches of the vaccine for a late-stage, decisive clinical trial scheduled to begin in the summer.
